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In the search for susceptibility loci predisposing to insulin resistance, previous studies have identified a glycine to arginine substitution at codon 972 (G972R) in the insulin receptor substrate-1 (IRS-1) gene as possibly being associated with impaired insulin action. The IRS-1 functions as a key proximal signalling molecule for both insulin receptor and the insulin-like growth factor-1 receptor signalling pathways. When phosphorilated, IRS-1 binds with high affinity proteins with src homology-2 domains, including phosphatidylinositol-3 kinase (PI-3 kinase) [1] . In vitro studies have shown that this mutation is associated with a substantial reduction in insulinstimulated PI-3 kinase activity and in binding of the P85 regulatory subunit of the PI-3 kinase to IRS-1 [2] . In transgenic animals, IRS-1 deficiency was associated with insulin resistance [3±4] and mice with null mutations in both insulin receptor and IRS-1 genes were shown to be insulin resistant with compensatory beta-cell hyperplasia [5] . It was originally reported that the IRS-1 codon 972 variant did not confer insulin resistance in subjects with Type II diabetes [6] . A more recent work [7] found, however, a 50 % decrease in insulin sensitivity in a small cohort of obese carriers of the G972R mutation. In addition, we recently found that the G972R mutation of the IRS-1 gene was associated with a significantly increased risk of coronary artery disease (CAD) [8] , particularly in obese subjects. Although these findings strongly suggest an interaction between this IRS-1 G972R mutation and obesity, no study has evaluated the possible effect of this gene variant on the development of obesity, particularly visceral obesity with which insulin resistance is predominantly associated. Moreover, the effect of the IRS-1 variant in aggravating the obesity-associated insulin resistance has not been fully explained.
To address these questions, we compared the prevalence of the G972R mutation in non-diabetic obese subjects and a group of lean subjects. Moreover, by investigating the relation between this IRS-1 mutation, measures of obesity (including body fat distribution, fat mass, fat free mass, FAT/FFM and basal metabolic rate) and metabolic parameters, we explored the possible influence of the G972R mutation on the relation between body fat distribution and insulin resistance.
Subjects and methods
Subjects. A total of 314 Caucasian subjects were studied. All subjects were recruited in the Lazio region of Italy, mostly from Rome and its surrounding towns. The 157 obese subjects were consecutively recruited from the obesity clinic of the Department of Clinical Science, University of Rome ªLa Sapienzaº. All obese patients were selected on the basis of a BMI higher than 30 kg/m 2 , in order to recruit strictly obese subjects, according to previously suggested criteria [9] . Body fat distribution was assessed by waist circumference (WC). The cut-off points chosen to differentiate central from peripheral obesity were the following: WC higher than 94 for men and WC higher than 88 for women. These limits involve a trade-off between sensitivity and specificity and were recently described [10] . Furthermore, these limits take into account the metabolic complications of the android biotype. Of these obese subjects, 105 underwent bioeletric impedance to determine fat-free mass, fat mass, basal metabolic rate and per cent total body water (Datasystem vers. 1, Medigroup, Milan, Italy). Total fat mass was calculated by subtracting fat-free mass (FFM) from total body weight. The accuracy of the FFM measurement was increased by using a multifrequency bioimpedence (1±5±10±50±100 KHz) and applying the equation described previously [11] . Exclusion criteria were: (1) the presence of Type II diabetes or first-grade relatives with Type II diabetes; (2) the presence of thyroid, liver or renal disease; (3) the presence of coronary artery disease (CAD).
Control subjects were 157 unrelated individuals selected at random from a population of individuals screened for CAD risk factors. Exclusion criteria were: (1) the presence of a BMI higher than 28; this cut-off point was set to avoid the risk of an overlap between the two groups of patients and control subjects, when recruiting moderately overweight subjects; (2) the presence of Type II diabetes or first-grade relatives with Type II diabetes; (3) the presence of CAD. The latter was excluded by use of the Rose questionnaire and electrocardiograms (Minnesota coding) [12] . In both obese and control subjects a complete medical history was obtained by questionnaire, which included questions about smoking habits, history of hypertension and Type II diabetes and current medication used. Diagnosis of Type II diabetes was based on history of hypoglycaemic treatment and a repeated fasting blood glucose higher than 126 mg/dl or both [13] ; that of hypertension was based on the presence of high systolic ( > 160 mmHg) and diastolic ( > 95 mmHg) blood pressure or both and the current use of antihypertensive medications or both.
Methods. The presence of glycine to arginine substitution at codon 972 of IRS-1 gene was determined as described previously [8] . Genotypes were scored by two independent investigators who did not know whether the samples were from a case patient or from a control subject. Ambiguous samples were analysed a second time.
Plasma insulin concentrations were measured on frozen samples using a radioimmunoassay (Biodata Insulin Kit, Milan, Italy ) with an inter-assay coefficient of variation of 7.5 %.
Homeostasis model assessment for insulin resistance (HOMA IR ) and for the percentage of beta-cell function were calculated as described previously [14] .
Categorical variables were compared by c 2 test or Fisher's exact test. Differences between continuous variables were evaluated by two-tailed Student's t-test. Genotype distributions between the study groups were compared by 2´2 and 2´3 contingency tables and c 2 analysis. Multiple regression analysis was used to find out whether there was an independent association between the G972R mutation and insulin resistance (HOMA IR ), after adjustment for other modulators known to affect both conditions (sex, age, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, BMI). A first-order interaction between obesity (BMI) and the IRS-1 variant was also included in the regression model. P-values < 0.05 were taken as statistically significant. All analyses were carried out using SPSS software programme Version 7.0.
Results
The clinical characteristics of the study subjects are shown in Table 1 . The obese subjects showed higher fasting insulin (p < 0.0001) and HOMA IR (p < 0.0001), indicating the presence of insulin resistance in this group. These differences remained significant after adjustment for age, sex and BMI. The percentage beta-cell function, fasting glucose and plasma lipids were not different between the two groups. Of the obese subjects, 105 were studied by bioeletric impedance, and were divided into subjects with central and peripheral obesity, according to their body fat distribution. This was assessed by waist circumference (WC), which provides a measure of upper body fat deposition and correlates with an increased risk of metabolic and cardiovascular complications [10] . When compared with subjects with peripheral obesity, those with central obesity had a higher BMI (35.5 1.7 vs 32.7 0.9, p < 0.002), a larger WC (108.9 5.0 vs 90.6 2.4, p < 0.0007), a higher fat mass and a lower FFM (p < 0.007, data not shown). Furthermore, HOMA IR was significantly higher in the subjects with central obesity (5.73 0.6 vs 3.99 0.3; p < 0.04), together with total cholesterol, total triglycerides and LDL cholesterol (p < 0.01, data not shown). Overall, these data confirm the expected finding of a worse metabolic profile in subjects with central obesity than in those with peripheral obesity.
Genotype distributions and allele frequencies in obese and control subjects are shown in Table 2 . Both groups were in Hardy-Weinberg equilibrium. The mutant G972R allele was significantly more frequent in obese subjects than in lean control subjects (p < 0.002) and no differences related to sex and age ªTotal obese subjectsº includes 50 patients who did not undergo biolectric impedance analysis a ªTotal obese vs control subjectsº: genotypes c 2 = 9.36, df = 2, p < 0.002; allele frequencies c 2 = 8.43, df = 1, p < 0.004 b ªCentral obese vs control subjectsº: genotypes c 2 = 10.21, df = 2, p < 0.006; allele frequencies c 2 = 10.04, df = 1, p < 0.001 c ªPeripheral obese vs control subjectsº: genotypes c 2 = 5.41, df = 1, p < 0.02; allele frequencies c 2 = 6.11, df = 1, p < 0.01 ªCentral obese subjects vs peripheral obese subjectsº: genotypes c 2 = 0.71, df = 2, p = NS; allele frequencies c 2 = 0.05, df = 1, p = NS. Cut-off points for centrally obese subjects were: WC ³ 94 for men and WC ³ 88 for women were found between the two groups. To test whether the G972R mutation could be associated with body fat distribution, we compared frequencies between the two sub-groups of obese subjects; however no significant difference was found between centrally obese and peripherally obese subjects. Similarly, the 105 obese carriers and non-carriers studied by biolectric impedance did not differ in all the other measures of adiposity (FFM, FAT, % TBW, basal metabolic rate). Both sub-groups were significant and independently different from the control subjects (Table 2) .
Assuming a dominant model of inheritance of the IRS-1 G972R mutation (only one homozygous detected for this mutation), we compared metabolic parameter between carriers (GR + RR) and non-carriers (GG) ( Table 3) . Obese carriers were younger and had a significantly higher BMI (p < 0.001). After adjustment for these differences, obese subjects carrying the IRS-1 variant showed higher plasma fasting insulin (p < 0.01), plasma tryglicerides (p < 0.03) and HOMA IR (p < 0.01) than obese non-carriers. Conversely, no differences were observed between G972R carriers and non-carriers among lean control subjects. These findings suggest that the G972R mutation affects insulin sensitivity in obese subjects. It should also be noted that higher triglycerides concentrations (although not significant) were observed in obese carriers, and this agrees with our previous observation [8] .
To estimate the independent contribution of the IRS-1 variant to insulin sensitivity (measured by HOMA IR ) we carried out multivariate analysis in obese and lean subjects to control for the confounding effect of well-known modulators of insulin resistance (sex, age, BMI, plasma lipids). In the regression model, we also included the interaction between BMI and the G972R mutation ( Table 4) . The results of multivariate analysis confirmed that the IRS-1 G972R mutation was an independent predictor of insulin sensitivity (p < 0.009) measured by HOMA IR in obese Data are given as means SEM. GG + GR = carriers; GG = non-carriers of IRS-1 mutation. a p < 0.001 obese carriers of G972R mutation vs obese non-carriers b p < 0.01 obese carriers of G972R mutation vs obese non-carriers, adjusted for age and BMI. c p < 0.001 obese carriers of G972R mutation vs obese non-carriers, adjusted for age and BMI.
d p < 0.03 obese carriers of G972R mutation vs obese non-carriers Differences between control carriers vs control non-carriers were all non-significant The statistical analysis of HOMA IR , total triglycerides and plasma insulin were done on log-transformed values but the untransformed values are given in subjects. Moreover BMI (p < 0.0001) and triglycerides (p < 0.01) were associated with insulin sensitivity in these subjects. The interaction between obesity and IRS-1 carrier status was even a stronger predictor of insulin resistance (p < 0.0001). Conversely none of these factors were associated with insulin sensitivity in lean control subjects.
Discussion
These data show that in our Italian cohort the G972R mutation of the IRS-1 gene is strongly associated with obesity, with almost 20 % of the obese subjects carrying this mutation. This frequency is similar to that found in previous studies [15, 16] in obese or insulinresistant subjects, where 18±25 % had the mutation. Other authors have not found an association between obesity and the G972 variant [17] . This study was, however, done on a different cohort (all female, much younger), and the control subjects were older women (mean age 59 years) showing a frequency of the G972R variant higher than that reported in the other association studies.
The frequency of the IRS-1 mutation was equally distributed between subjects with central and peripheral obesity, indicating that this mutation is probably not involved in body fat distribution. In univariate analysis this mutation associates with reduced insulin sensitivity in obese subjects, with carriers being two times more insulin resistant than non-carriers. This finding was confirmed by multivariate analysis showing that among obese subjects the IRS-1 variant was a significant, independent predictor of insulin resistance. These conclusions, extending previous observations [7] , suggest an apparent synergistic interaction between the G972R mutation and obesity to worsen insulin resistance. Our results are also in agreement with others recently presented [18] that found this variant to be associated with an increase in BMI in a large African-American cohort. This study did not find any association between the G972R mutation and severe obesity (BMI > 40) but the discrepancy could be explained by the fact that severe obesity could recognise other hormonal and environmental influences. It also did not find any effect of IRS-1 variant on plasma insulin concentrations [18] ; fasting insulin used as a surrogate index for insulin sensitivity cannot, however, explain more than 30±40 % of the variance in glucose-derived insulin sensitivity [19] , whereas HOMA IR correlation with clamp is about 0.80 [20] . Therefore, a better measure of insulin sensitivity might have increased the possibility of finding an association.
Two other studies have attempted to correlate the G972R variant to insulin sensitivity by using hyperinsulinaemic euglycaemic clamp in carriers of the mutation [21, 22] , without postive results. Both studies, however, had low BMI cut-off values. In particular, one report [21] studied Type II diabetic Japanese patients with a mean BMI of 22.1, and since overt diabetes is probably the result of several defects in insulin action, it is possible that the effect of the G972R mutation might have been diluted. The other study [22] was also carried out on subjects with a much lower BMI (mean BMI = 25) than our subjects, thus making it difficult to detect the possible interaction between obesity and the IRS-1 variant.
A possible effect of the G972R mutation of the IRS-1 gene on impairing insulin secretion has been proposed [23] . Compensatory beta-cell hyperplasia in mice with null mutation in the IRS-1 gene has, however, been shown by others [5] . Several human studies [7, 18, 21] , have also failed to find differences in fasting plasma insulin and C peptide or both in carriers of the G972R mutation. In our cohort, we did not find any difference in insulin levels or in the percent of beta-cell function between our groups. The question of the effect of the G972R mutation on insulin secretion remains open and further studies are necessary.
The mechanisms behind the interaction between the IRS-1 gene variant, obesity and insulin resistance are still not known. A defective response to known modulators of insulin signalling, such as TNF-a, an increased serine phosphorylation which would predict impaired insulin signalling or a defective interaction with IRS-1 direct substrates, such as PI3-K, have all been suggested. Molecular studies of the effect of the G972R mutation are warranted to answer these questions.
In conclusion, the G972R mutation of the IRS-1 gene strongly associates with obesity in this Italian cohort, and, within the obese group, it was associated with metabolic parameters suggesting greater insulin resistance. This association indicates a possible interaction between the IRS-1 variant and obesity to worsen insulin sensitivity. These observations support our previous observation that this IRS-1 gene variant could increase coronary risk in obese subjects by favouring pro-atherogenic metabolic abnormalities.
